Acea Bio   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: San Diego CA United States (2002)
Status: Acquired by Sorrento Therapeutics, Inc. (2021)

Organization Overview

First Clinical Trial
2009
NCT01361529
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2024

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Acea Bio (Hangzhou) Co., Ltd. | ACEA Therapeutics, Inc. | Hangzhou ACEA Pharmaceutical Research Co., Ltd. | Hangzhou ACEA Pharmaceutical Research Co.,Ltd. | Zhejiang ACEA Pharmaceutical Co. Ltd.

Active Ingredients

Drugs in Phase 3 Trials (4)

abivertinib (1 trial)

cisplatin (platinol) (1 trial)

gefitinib (iressa) (1 trial)

sti-1558 (5 trials)

Drugs in Phase 2 Trials (2)

ac0010ma (7 trials)

sti-6129 (1 trial)

Drugs in Phase 1 Trials (5)

ac0058ta (2 trials)

fluorapacin (1 trial)

itraconazole (sporanox) (1 trial)

rifampin (1 trial)

sti-8591 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Non-Small-Cell Lung (Phase 3)

Lung Neoplasms (Phase 3)

Lupus Erythematosus, Systemic (Phase 1)

Lymphoma (Phase 1)

Lymphoma, B-Cell (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 19
  • # of Trial APIs: 11